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ABSTRACT 
 
Previous studies indicated that patients with atherosclerosis are predominantly infected by human 
cytomegalovirus (HCMV), but rarely infected by type 1 Epstein-Barr virus (EBV-1). In this study, 
atheromas of 30 patients who underwent aortocoronary bypass surgery with coronary endartherectomy 
were tested for the presence of these two viruses. HCMV occurred in 93.3% of the samples and EBV-1 
was present in 50% of them. Concurrent presence of both pathogens was detected in 43.3% of the samples.  
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Atherosclerosis, considered the main underlying disease 
responsible for cardiovascular and cerebrovascular events, has 
multifactor etiology. Obesity, hyperlipidemia, diabetes, 
hypertension and cigarette smoking account for 50 to 60 
percent of cases of cardiovascular disease (10). Atherosclerosis 
essentially develops from a mild chronic inflammatory reaction 
to an injury and there is evidence that infectious 
microorganisms, such as Chlamydia pneumonia, Helicobacter 
pylori, periodontal pathogens, human cytomegalovirus 
(HCMV), hepatitis A virus, enterovirus and Epstein-Barr virus 
(EBV) may play a pathogenic role (4,15,20).  
The latent state of viral infections might differ from that of 
bacterial infections, and Herpesviridae in particular exert direct 
proatherogenic effects on injured vessel walls (5). Viruses may 
directly infect arterial intima, inducing or accelerating 
atherosclerosis. Moreover, viral infections may promote 
atherosclerosis by increasing the expression of adhesion 
molecules and inflammatory cytokines (13) and procoagulant 
effects (8), and enhancing cholesterol uptake (14) as well as 
auto-immune response to infection (6). There is experimental 
evidence that HCMV can infect human coronary smooth 
muscle cells and initiate viral replication (12), while EBV can 
have a lifelong persistence in B cells (17). HCMV has been 
implicated in atherogenesis, and restesnosis after coronary 
angioplasty and transplant vasculopathy (9). 
Seroepidemiological studies have implicated EBV in 
atherosclerosis (19) although only one study detected EBV in 
atherosclerotic aortic tissue (18). 
The objective of the present study was to detect HCMV 
and EBV-1 in atherosclerotic plaques from patients who 
underwent coronary endartherectomy. 
This study was approved by the Ethical Committee of the 
Evangélico Hospital (Londrina – Paraná) and all patients 
signed the informed consent form. Thirty patients (mean age
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61+11.5 years, 76.6% male) with symptomatic coronary artery 
disease were enrolled. All patients underwent aortocoronary 
bypass surgery with coronary endartherectomy. An atheroma 
was taken from each patient’s infarct-related artery and the 
tissue was stored at -70°C with RNAlater (Applied 
Biosystems) until DNA extraction. DNA was extracted from 
each atheroma using Chargeswitch® Gdna Tissue Kits 
(Invitrogen, São Paulo, Brazil) according to the manufacturer 
instructions. 
Nested-PCR was used to detect viral DNA using specific 
oligonucleotides for EBV-1 and HCMV. EBV-1 primers 
amplified a fragment of EBV nuclear antigens EBNA 2 and 
HCMV primers amplified a fragment of glycoprotein B gene. 
The outer and inner oligonucleotides primers used in the tests, 
the temperature of melting and the product length are described 
in Table 1. 
 
 
Table 1.  PCR primers, temperature of melting (TM) and amplicon length (base pairs) in the identification of the infectious agents 
Infectious agent 
(blast accession) 
Primer                                   TM 
ºC 
Amplicon 
length 
Reference 
Epstein Barr virus 
type I 
(S71027) 
1º round  5'- AGGGATGCCTGGACACAAGA-3'    
                5'-TGTGCTGGTGCTGCTGGTGG-3' 
2ºround: 5'-AACTTCAACCCACACCATCA-3'    
               5'-TTCTGGACTATCTGGATCAT-3' 
 
56 
 
46 
602 
 
116 7 
Human 
Cytomegalovirus 
(X17403) 
1º round  5’ GAGGACAACGAAATCCTGTTGGGCA-3 
                5’-TCGACGGTGGAGATACTGCTGAGG-3’ 
2ºround  5’-ACCACCGCACTGAGGAATGTCAG-3’ 
               5’-TCAATCATGCGTTTGAAGAGGTA-3’ 
56 
 
50 
 
150 
 
100 
3
 
 
 
PCR was performed with a final volume of 25l mixture 
containing 25pmol of each primer (Invitrogen, Carlsbad CA), 
1U Taq platinum DNA polymerase (Invitrogen), 50 mM 
MgCl2, 0.05mM dNTP mix and 1 to 10 l of extracted DNA 
sample.  
The PCR conditions were optimized for the different 
primers using as a basis one initial denaturation cycle at 94°C 
for 3 min, followed by 35 cycles of denaturation at 94°C for 1 
min, annealing at 60°C for 1 min for the first round of EBV-1, 
at 55°C for 1 min for the second round of EBV-1, at 56°C for 
50 s for the first round of HCMV , at 57°C for 50 s for the  
second round of HCMV, extension at 72°C for 1 min, and a 
final extension step at 72°C for 7 min.  
All specimens were tested in duplicates to each of the 
target microorganisms. Negative and positive controls were 
included in every reaction: DNA free mix as negative control, 
and DNA from EBV positive cell B lymphoma diagnosed in 
our laboratory as positive control for EBV. The Laboratory of 
Virology of University of São Paulo provided the control for 
HCMV. Detection of PCR products was performed by 
electrophoresis in a 2% agarose gel containing 0.5g/ml 
ethidium bromide. 
A total of 30 coronary atheroma specimens were 
investigated. PCR for HCMV yielded positive results for 28 
samples (93.3%), whereas EBV-1 was detected in 15 samples 
(50%). At least one of the viruses was detected in every C. 
Concurrent infection with HCMV and EBV-1 was observed in 
13 specimens (43.3%) (Table 2). 
 
Table 2. Positivity for Epstein-Barr-1 virus (EBV-1) and 
human cytomegalovirus (HCMV) in 30 atheroma samples. 
  viral detection 
EBV-1+/ HCMV - 2 
EBV-1 -/HCMV+ 15 
EBV-1 + /HCMV+ 13 
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This study detected DNA from HCMV in most coronary 
atherosclerotic lesions and indicated that concurrent infection 
with EBV-1 is also frequent. The high incidence of HCMV in 
coronary arteries wall of patients suffering from atherosclerosis 
has also been reported by Hendrix et al. (15), although Shi & 
Tokunaga (18) detected HCMV in 40% of atherosclerotic 
aortic tissue. In our study, 50% of the coronary artery 
atheromas were positive to EBV-1. HCMV DNA in 
atherosclerotic tissue was reported for the first time by Shi & 
Tokunaga (18) in 8 out of 10 atherosclerotic aortic tissues from 
autopsies.  
Most studies implicate HCMV infection with greater risk 
of accelerated atherosclerosis following heart transplantation 
(12) and restenosis following coronary atherectomy (22). 
Grahame-Clarke et al. (11) showed that relatively young 
asymptomatic individuals seropositive for HCMV have 
abnormal vascular reactivity consistent with endothelial 
dysfunction. Their results also suggest that previous HCMV 
infection might be associated with increased atherosclerotic 
burden, as assessed by coronary artery calcification. HCMV 
infection has been shown to upregulate IL-6 gene expression 
(16) and cytokine production itself (1). Mediated by this 
systemic inflammatory process, HCMV infection might 
contribute to the atherosclerotic and atherothrombotic 
processes, as reported by Blankenberg et al. (2). These authors 
concluded that HCMV seroposivity in patients with an 
inflammatory response is independently associated with future 
cardiac mortality. Since this study detected HCMV in 93.3% of 
coronary atheromas, this virus may be strongly implicated in 
the etiology of atherosclerosis.  
Our results indicate that 43.3% of the samples contained 
both HCMV and EBV-1 DNA.  It has been shown that the 
aggregate number of pathogens to which an individual had 
been exposed might be involved in the pathogenesis of 
atherosclerosis (infectious burden). This concept was 
demonstrated in cross-sectional as well as prospective studies 
(5, 23, 24). Rupprecht et al. (20) identified EBV as the 
strongest independently predictive of future death from 
cardiovascular causes and showed for the first time that prior 
infection to EBV may influence the course of atherosclerosis. 
Herpesviridae in a latent state may contribute to the 
atherogenic process independently of an inflammatory 
response. A controlled trial using antiviral substances for the 
prevention of atherosclerosis and restesnosis after coronary 
bypass surgery or angioplasty seems justifiable. 
This study confirms that HCMV and/or EBV-1 DNA are 
present in coronary arteries atheromas and the association of 
both viruses is frequent. Clinical implications of this 
association and the pathogenic impact on atherosclerosis 
should be further investigated. 
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